Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Stock Information for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Pulse Biosciences, Inc. (NASDAQ: PLSE)
Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024
Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
Pulse Biosciences, Inc. Announces the Closing of its Rights Offering
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.